Lansoprazole
- Atc Codes:A02BC03
- CAS Codes:103577-45-3
- PHARMGKB ID:103577-45-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Agopton, Lansobene, Lansohexal, Lansonorm, Lansoprazol; Belgium: Dakar, Lansoprazol, Lansoprazole; Bulgaria: Lansoprol; Cyprus: Lasoprol; Czech Republic: Lansoprazol, Lansoprol, Lansoram, Lanzul; Denmark: Lansoprazol; Estonia: Lanobax, Lansoprazol, Lanzostad, Lanzul; Finland: Gasterix, Helipak, Lanrec, Lansoprazol, Lantil, Lanvone, Prazotad, Sepol, Zolt; France: Lansoprazole, Lanzor, Ogast, Ogastoro; Germany: Agopton; Lanso, Lansoprazol, Lansosiga, Lansox, Lanzoprazol, Lanzor, Zoton; Greece: Apradil, Lanciprol, Lanso, Lanzol, Laprazol, Prevacid, Ulced, Zoletad; Hungary: Lansone; Ireland: Bylans, Lansoprazole, Lanziop, Lanzol, Razolager, Zomel, Zoton, Zotrole; Italy: Ermes, Eugastran, Frilans, Krovaneg, Lansoprazolo, Lansox, Levogenix, Limpidex, Lomevel, Peptirex, Pergastid, Zoton; Latvia: Lanobax, Lansoprazol, Lanzole, Lanzostad, Lanzul, Pylokit; Lithuania: Lanobax, Lansoprazol, Lanzostad, Lanzul; Luxembourg: Dakar; Malta: Lasoprol, Lansoprazole; Netherlands: Lansoprazol, Lanzatol, Ogastro, Prezal; Poland: Lanbax, Lansolek, Lansoprazole, Lansoprazolum, Lantrea, Lanzogen, Lanzostad, Lanzul, Opatin, Rapilazole, Renazol, Zalanzo; Portugal: Alexin, Belmural, Dispepci, Gastrex, Gastribien, Gastroliber, Lansoprazol, Lanzogastro, Lapol, Ogasto, Pampe, Ulcertec; Romania: Lansoprazol, Lanzap, Lanzogastro, Lanzol; Lanzul, Levant-Ranbaxy; Slovakia: Lansoprazole, Lansoram, Lanzul; Slovenia: Lansoprazol, Lantrea, Lanzul; Spain: Bamalite, Estomil, Lansoprazol, Lanzol, Monolitum, Opiren, Pasgram, Pro-Ulco, Protoner; Sweden: Lanipizin, Lansolidix, Lansoprazol, Lanzo, Linepizin, Nixacid, Zoton; UK: Lansoprazole, Zoton.
North America
Canada: Lansoprazole, Prevacid; USA: Lansoprazole, Prevacid.
Latin America
Argentina: Lanzoacid, Lanzopral, Mesactol; Brazil: Alkazol, Lanogastro, Lansoprazol, Lanz, Lanzol, Lanzopept, Neozol, Ogastro, Prazol-Medley; Mexico: Amdory, Arular, Bonzol, Gavonad, Ilsatec, Imidex, Keval, Lafin, Lanodizol, Lansoprazol, Mavilan, Mediprim, Ogastro, Olan, Palatrin, Pranix, Safemar, Serax, Uldapril, Ulpax.
Asia
Japan: Lansoprazole, Lansoral, Laprazol, Lasopran, Stanzome, Taiproton, Takepron, Tapizol.
Drug combinations
Lansoprazole and Naproxen
Lansoprazole, Amoxicillin, and Clarithromycin
Lansoprazole, Amoxicillin, and Metronidazole
Lansoprazole, Metronidazole, and Tetracycline
Chemistry
Lansoprazole: C~16~H~14~F~3~N~3~O~2~S. Mw: 369.36. (1) 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; (2) 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole. CAS-103577-45-3 (1989).
Pharmacologic Category
Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors; Substituted Benzimidazole. (ATC-Code: A02BC03).
Mechanism of action
Decreases acid secretion in gastric parietal cells through inhibition of (H^+^, K^+^)-ATPase enzyme system, blocking final step in gastric acid production.
Therapeutic use
Short-term treatment of active duodenal ulcers. Maintenance treatment of healed duodenal ulcers. As part of a multidrug regimen for H. pylori eradication. Short-term treatment of active benign gastric ulcer. Treatment of NSAID-associated gastric ulcer. Short-term treatment of symptomatic gastroesophageal reflux disease. Short-term treatment for all grades of erosive esophagitis. To maintain healing of erosive esophagitis. Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Pregnancy and lactiation implications
Animal studies have not shown teratogenic effects on the fetus. There are as yet no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to lansoprazole, substituted benzimidazoles (i.e. esomeprazole, omeprazole, pantoprazole, rabeprazole), or any component of the formulation.
Warnings and precautions
Might cause atrophic gastritis. No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia. Relief of symptoms does not preclude presence of gastric malignancy. Caution in severe liver dysfunction. Some preparations contain phenylalanine. Administration of proton-pump inhibitors associated with increased risk for developing certain infections (e.g. community-acquired pneumonia).